Editorial Policies
- COPE Recommendation for Conflict of Interest (specific to editors)
- Conflict of Interest and Financial Disclosures (specific to editors)
- Peer Review Process
- Advertisement Policies
- Editorial Policies
- Publisher Policies
- COPE Recommendation for Plagiarism
- Publication Ethics and Malpractice Statement
- Editorial Process
- Creative Commons License
- COPE Recommendation for Conflict of Interest (Specific to Editors)
The Indo-American Journal of Pharma and Bio Sciences adheres to the guidelines set by the Committee on Publication Ethics (COPE) regarding conflicts of interest (COI) for its editorial board members. Editors must disclose any personal, financial, or professional relationships that could influence their editorial decisions or the peer review process. This includes any affiliations with organizations, funding sources, or personal connections that might lead to biased judgment, either directly or indirectly, when handling submissions. The journal's editorial team is committed to maintaining objectivity, fairness, and impartiality in the editorial process. If an editor has a conflict of interest related to a particular manuscript, they must recuse themselves from handling the submission and recommend another editor to oversee the review and decision-making process. The Indo-American Journal of Pharma and Bio Sciences ensures that editors understand their obligations under COPE’s recommendations and enforces strict adherence to these standards. The editorial board undergoes periodic training on COI issues to promote transparency and prevent ethical lapses in the publishing process. The journal emphasizes that the editorial decision-making process should be based solely on the scientific merit of the manuscript and its relevance to the field of pharmaceutical and biosciences research. Any conflict of interest is transparently disclosed to authors and reviewers. COI issues that are not disclosed may result in the retraction of decisions or further investigation in accordance with COPE guidelines.
2. Conflict of Interest and Financial Disclosures (Specific to Editors)
The Indo-American Journal of Pharma and Bio Sciences follows strict policies regarding conflicts of interest (COI) and financial disclosures for its editorial board. To uphold the highest standards of integrity, editors are required to disclose any potential conflicts of interest that might influence their editorial decisions. These include financial relationships with pharmaceutical companies, research funding organizations, or any other entities that may have a direct or indirect interest in the content being published. Editors must also disclose any personal relationships or affiliations that could compromise their impartiality in handling submissions. The journal mandates that editors report all relevant financial support or potential conflicts prior to taking on their editorial roles. This transparency ensures that decisions are made based solely on the scientific validity and merit of submitted manuscripts, without external influences. Editors who are involved in the submission process for an article related to their own work or research interests must declare this conflict, and another editor will be assigned to handle the manuscript. By enforcing this policy, the Indo-American Journal of Pharma and Bio Sciences ensures an unbiased, ethical, and transparent review process, free from any undue influence. This policy is in line with COPE's guidelines and ensures that the editorial process aligns with the journal's commitment to high-quality, unbiased academic publishing.
3. Peer Review Process
The Indo-American Journal of Pharma and Bio Sciences employs a double-blind peer review process to ensure a rigorous, fair, and impartial evaluation of all submitted manuscripts. In this system, both the identities of the authors and the reviewers are kept confidential to reduce potential biases in the review process. Upon submission, the manuscript undergoes an initial screening by the editorial team to ensure it aligns with the journal’s scope and basic quality standards. If the manuscript is deemed suitable, it is then sent out to two or more independent expert reviewers in the field of pharmaceutical sciences or biosciences. These reviewers evaluate the manuscript’s methodology, data analysis, and conclusions, and provide constructive feedback on how to improve the paper. The reviewers are asked to assess the manuscript’s originality, relevance, and scientific merit, as well as its ethical compliance. Based on the reviewers' feedback, the editorial team makes the final decision—whether to accept, revise, or reject the manuscript. The journal aims to ensure that peer reviewers are highly qualified and have no conflicts of interest with the authors or subject matter. Authors are given an opportunity to revise their manuscripts in response to reviewers' comments, and the revised manuscripts are typically reviewed again before a final decision is made. This peer review process upholds the scientific rigor and credibility of the journal and ensures that only high-quality research is published.
4. Advertisement Policies
The Indo-American Journal of Pharma and Bio Sciences adopts a clear advertisement policy to maintain the integrity and neutrality of its content. The journal accepts advertisements that are relevant to the academic and research communities, such as those for books, conferences, research tools, or professional services that align with the focus of the journal—pharmaceutical sciences, biosciences, and related fields. However, all advertisements must be clearly distinguishable from editorial content and must not influence or conflict with the scientific nature of the published research. The journal maintains strict editorial independence, and any advertising content will not be placed within or adjacent to articles or other scholarly content. Advertisers must comply with ethical guidelines that respect the professional and educational objectives of the journal. The editorial team has the authority to review and approve all advertisements before publication, ensuring that no ads promote products or services that could be deemed unethical or misleading, particularly in areas related to pharmaceuticals or healthcare. The journal reserves the right to reject advertisements that do not align with its standards or the values of academic publishing. The Indo-American Journal of Pharma and Bio Sciences works to balance the financial needs of the journal with its commitment to maintaining a high standard of academic integrity, ensuring that advertisements do not compromise the quality of the scholarly content presented to its readers.
5. Editorial Policies
The Indo-American Journal of Pharma and Bio Sciences follows a comprehensive set of editorial policies designed to ensure the quality, ethics, and transparency of the publication process. These policies encompass the responsibilities of the editors, authors, reviewers, and the journal’s commitment to maintaining the highest academic standards. Editors are responsible for making impartial and fair decisions on manuscripts based on their scientific merit, the quality of the research, and its relevance to the field of pharmaceutical and biosciences. The editorial board ensures that all manuscripts are subjected to a rigorous peer review process, following the principles of fairness and confidentiality. Additionally, the journal adheres to international ethical guidelines, including those related to plagiarism, conflicts of interest, and research involving human and animal subjects. Authors are required to submit original, unpublished work and to disclose any conflicts of interest or funding sources related to their research. Reviewers are expected to provide objective, constructive feedback while maintaining the confidentiality of the submitted manuscript. The journal’s editorial policies also extend to ensuring the accuracy of published content, addressing ethical issues such as retractions or corrections when necessary, and promoting transparency in data sharing. These editorial policies are reviewed regularly to ensure compliance with best practices in academic publishing, and the journal is committed to maintaining high standards of quality and integrity in all aspects of its operations.
6. Publisher Policies
The Indo-American Journal of Pharma and Bio Sciences is committed to upholding high standards of publishing ethics and professional conduct. The journal is published by a reputable academic publisher that adheres to established policies for transparent, ethical, and high-quality scholarly publishing. These policies are designed to foster trust in the academic community and ensure that the journal’s operations comply with international standards. The publisher guarantees that all manuscripts undergo rigorous peer review, following clear guidelines for evaluating scientific rigor, originality, and ethical compliance. The publisher also ensures that the journal remains open access, providing free access to all published content for readers globally, which is fundamental to the journal’s mission of disseminating knowledge widely. Additionally, the publisher adheres to best practices regarding copyright, licensing, and intellectual property, ensuring that authors retain the rights to their work while granting the journal a license to distribute and publish the research. The publisher follows the COPE guidelines for handling complaints, conflicts of interest, retractions, and corrections. The publisher also promotes transparency in its publishing process, ensuring that the editorial process is free from external influences. The journal’s publisher works in close collaboration with the editorial team to provide ongoing support for the journal’s operations, including financial support for open access and ensuring compliance with the latest technological advancements in academic publishing.
10. Creative Commons License
The Indo-American Journal of Pharma and Bio Sciences utilizes the Creative Commons (CC) license to promote open access and ensure that published works are freely available for non-commercial use, adaptation, and redistribution. Typically, the journal adopts the CC BY (Attribution) license, which allows others to remix, tweak, and build upon the original work, even for commercial purposes, as long as proper credit is given to the author. This license supports the journal’s commitment to openness and the global dissemination of scientific knowledge. Authors are informed about licensing options when submitting their work, and those who choose the CC license ensure that their research is widely accessible, contributing to the advancement of knowledge in pharmaceutical and biosciences fields. The CC license enhances the impact of the journal’s published content, as it allows readers to reuse and redistribute research without paywalls, fostering greater collaboration and innovation within the scientific community.
